Xcout Intel
BioVersys AG competitors & alternatives
The 12 closest competitors and alternatives to BioVersys AG among biotechnology companies — ranked by similarity to what BioVersys AG actually does, not by market-cap band.
Subscribe to see BioVersys AG’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About BioVersys AG
BioVersys AG is an award-winning, privately-owned Swiss pharmaceutical and biotech company headquartered in Basel, Switzerland, focused on the research and development of antibacterial treatments for drug-resistant bacterial infections.
BioVersys AG at a glance
BioVersys AG is a biotechnology company headquartered in Switzerland. Xcout tracks 6 named people at BioVersys AG, including Seng Chin Mah (Chairman).
BioVersys AG leadership
- Seng Chin MahChairman
- Marc GitzingerBoard Member & CEO
- David HunstadBoard Member
- Marina von SchönauBoard Member
- Simona SkerjanecBoard Member
- Ulrik SchulzeBoard Member
Top 12 BioVersys AG competitors
Ranked by semantic similarity — how close each company is to BioVersys AG by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Biotech
Bugworks Research Inc. is a clinical-stage biopharmaceutical company headquartered in Bangalore, India, developing novel therapeutics to combat antimicrobial resistance.
Biotech
Omnix Medical is a biopharmaceutical company that develops novel antibiotic agents and antimicrobial peptides to treat infections caused by drug-resistant bacteria. The company focuses on creating first-in-its-class anti-infective therapeutics, such as its lead compound OMN6, to target life-threatening bacterial strains.
Similar biotechnology company
Akagera Medicines is a private Delaware-registered company headquartered in Boston, Massachusetts. The company develops novel and patented liposomal formulations of antibacterial drugs.
Similar biotechnology company
LimmaTech Biologics is a Swiss clinical-stage biotechnology company developing vaccines against bacterial infections, including drug-resistant pathogens. Its work includes conjugate vaccine candidates for Shigella and other diseases, serving pharmaceutical partners and ultimately patients at risk of serious bacterial infections.
Similar biotechnology company
Obulytix is a biotechnology startup founded in 2023 and headquartered in Ghent, Belgium, focused on advancing antimicrobial innovation and building the future of antibiotics.
Similar biotechnology company
Evrys Bio, LLC is a biotechnology company developing first-in-class therapeutics designed to treat a broad spectrum of viral infections and prevent drug resistance. The company utilizes allosteric, small molecule SIRT2 modulators that target host cells to suppress viral infections and shift metabolic reprogramming.
Similar biotechnology company
Vaxdyn is a Seville-based biotechnology spin-off founded in 2011 that develops safe and effective multi-pathogen vaccines to prevent dangerous bacterial infections.
Similar biotechnology company
Memo Therapeutics AG (MTx) is a late-stage biotech company focused on developing best-in-class therapeutic antibodies. The company aims to transform the lives of patients with viral infections and has shown encouraging Phase II data.
Similar biotechnology company
Vaderis Therapeutics AG is a clinical-stage biotechnology company focused on developing novel treatments for severe vascular diseases. The company is headquartered in Basel, Switzerland.
Similar biotechnology company
TXN Systems AB is a healthcare company developing an innovative antibiotic regimen targeted at treating complicated urinary tract infections caused by antibiotic-resistant bacteria.
Similar biotechnology company
C3J Therapeutics, Inc. is a clinical-stage biotechnology company based in Los Angeles, California, focused on improving human health through the development of targeted antimicrobials.
Similar biotechnology company
AMR Bio is a clinical-stage biotechnology company headquartered in London, United Kingdom, focused on infection prevention and antimicrobial resistance. The company is dedicated to developing novel anti-infectives, including its Phase 3-ready, first-in-class topical antimicrobial candidate XF-73.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of BioVersys AG and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for BioVersys AGand every competitor above — in one live dashboard.
Subscribe to Xcout Intel →